Mitsui Fudosan and Stanhope have secured another Life Sciences tenant for White City Place, with GammaDelta Therapeutics taking up approximately 12,000 sq ft of office and lab space in the WestWorks building from April 2019.
Alongside fellow innovators Novartis, Autolus and Synthace, GammaDelta are the latest life sciences company to move to the 1.9 million sq ft business, innovation and life sciences district at White City.
The move to White City forms part of the company’s expansion plan following Japan’s Takeda Pharmaceutical Company and another backer agreeing to invest $100 million into their research and development funding.
GammaDelta will continue their work in developing immunotherapies for a range of malignant diseases at WestWorks, in tandem with their research facility located at Imperial College’s newly developed Imperial West campus.
This letting further cements White City Place’s growing reputation, alongside the pioneering facilities offered by Imperial College, such as The Molecular Science Research Hub and The Translation & Innovation Hub (I-HUB), as one of the UK’s leading life sciences and technology districts with over 100,000 sq ft leased to this sector in 2018.
Eiichiro Onozawa, Managing Director of Mitsui Fudosan, said: “The arrival of GammaDelta to WestWorks highlights once again the transformation of the area into a hub of scientific and technological innovation.
With the renovation of White City Place and the development of Imperial College’s new campus, White City has asserted itself as the destination of choice for any life sciences company looking to bring their exciting ideas and new approaches to London”